trending Market Intelligence /marketintelligence/en/news-insights/trending/be9TPmmxwM1J5sN8ymNXaQ2 content esgSubNav
In This List

Calif.-based AnaptysBio prices IPO

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Calif.-based AnaptysBio prices IPO

AnaptysBio Inc. priced its initial public offering at $15 apiece.

The Calif.-based biotechnology company is looking to issue 5 million shares once it goes public. AnaptysBio has also granted underwriters a 30-day option to purchase up to an additional 750,000 of the shares offered.

The offering is expected to close Jan. 31.

Credit Suisse and Stifel are acting as joint book-running managers for the offering. JMP Securities and Wedbush PacGrow are acting as co-managers.

AnaptysBio is developing treatments for inflammation and cancers.